依维莫司联合内分泌治疗用于绝经后激素受体阳性HER2阴性晚期乳腺癌
BOLERO-4是一项多中心、开放标签、单臂2期试验,纳入202例绝经后ER阳性HER2阴性晚期乳腺癌患者,一线接受依维莫司10 mg/d联合来曲唑2.5 mg/d治疗。中位无进展生存期为22.0个月(95%CI 18.1-25.1),24个月总生存率为78.7%(95%CI 72.1%-83.9%)。结论提示该联合方案可作为一线治疗选择。
要点
- 一线依维莫司联合来曲唑中位PFS为22.0个月(95%CI 18.1-25.1)。
- 24个月总生存率为78.7%(95%CI 72.1%-83.9%),中位OS未达到。
- 一线最常见全等级不良事件为口腔炎(68.8%),最常见3-4级为贫血(10.4%)。
核心结论
- 依维莫司联合内分泌治疗可能是绝经后ER阳性HER2阴性晚期乳腺癌的良好一线治疗选择。
研究设计与样本
- 多中心、开放标签、单臂2期BOLERO-4试验,筛查245例,入组202例,中位随访29.5个月。
- 一线方案为依维莫司10 mg/d联合来曲唑2.5 mg/d;疾病进展后由研究者决定是否接受二线依维莫司10 mg/d联合依西美坦25 mg/d。
主要发现
- 一线治疗中位无进展生存期为22.0个月(95%CI 18.1-25.1个月)。
- 中位总生存未达到,24个月估计总生存率为78.7%(95%CI 72.1%-83.9%)。
- 50例患者开始二线治疗,中位无进展生存期为3.7个月(95%CI 1.9-7.4个月)。
- 一线最常见全等级不良事件为口腔炎(139例,68.8%),最常见3-4级不良事件为贫血(21例,10.4%)。
- 二线最常见不良事件为口腔炎和体重下降(各10例,20.0%),最常见3-4级不良事件为高血压(5例,10.0%)。
关键数值与推荐
- 一线主要终点为研究者根据RECIST 1.0评估的无进展生存期。
- 安全性分析纳入至少接受1剂研究药物且至少完成1次基线后安全性评估的患者。
临床怎么用
- 对于绝经后ER阳性HER2阴性晚期乳腺癌患者,可考虑一线使用依维莫司联合来曲唑。
- 治疗期间需关注口腔炎和贫血等不良事件。
局限性
- 本研究为单臂2期试验,无随机对照。
- 二线治疗样本量较小(50例),结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. OBJECTIVE: To investigate the combination of everolimus plus endocrine therapy in first-line and second-line treatment settings for postmenopausal women with estrogen receptor-positive, human epidermal growth receptor 2-negative advanced breast cancer. DESIGN, SETTING, AND PARTICIPANTS: In the multicenter, open-label, single-arm, phase 2 BOLERO-4 (Breast Cancer Trials of Oral Everolimus) clinical trial, 245 patients were screened for eligibility; 202 were enrolled between March 7, 2013, and December 17, 2014. A median follow-up of 29.5 months had been achieved by the data cutoff date (December 17, 2016). INTERVENTIONS: Patients received first-line treatment with everolimus, 10 mg/d, plus letrozole, 2.5 mg/d. Second-line treatment with everolimus, 10 mg/d, plus exemestane, 25 mg/d, was offered at the investigator's discretion upon initial disease progression. MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival in the first-line setting per Response Evaluation Criteria in Solid Tumors, version 1.0. Safety was assessed in patients who received at least 1 dose of study medication and at least 1 postbaseline safety assessment. RESULTS: A total of 202 women treated in the first-line setting had a median age of 64.0 years (interquartile range, 58.0-70.0 years) with metastatic (194 [96.0%]) or locally advanced (8 [4.0%]) breast cancer. Median progression-free survival was 22.0 months (95% CI, 18.1-25.1 months) with everolimus and letrozole. Median overall survival was not reached; 24-month estimated overall survival rate was 78.7% (95% CI, 72.1%-83.9%). Fifty patients started second-line treatment; median progression-free survival was 3.7 months (95% CI, 1.9-7.4 months). No new safety signals were observed. In the first-line setting, the most common all-grade adverse event was stomatitis (139 [68.8%]); the most common grade 3 to 4 adverse event was anemia (21 [10.4%]). In the second-line setting, the most common adverse events were stomatitis and decreased weight (10 [20.0%] each); the most common grade 3 to 4 adverse event was hypertension (5 [10.0%]). There were 50 (24.8%) deaths overall during the study; 40 were due to study indication (breast cancer). CONCLUSIONS AND RELEVANCE: The results of this trial add to the existing body of evidence suggesting that everolimus plus endocrine therapy is a good first-line treatment option for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01698918.
引用
- Royce M, Bachelot T, Villanueva C, et al. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018. PMID: 29566104. doi:10.1001/jamaoncol.2018.0060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。